ImpediMed Ltd
ASX:IPD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.044
0.155
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IPD stock under the Base Case scenario is 0.079 AUD. Compared to the current market price of 0.055 AUD, ImpediMed Ltd is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ImpediMed Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IPD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
ImpediMed Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ImpediMed Ltd
Balance Sheet Decomposition
ImpediMed Ltd
Current Assets | 29.5m |
Cash & Short-Term Investments | 24.6m |
Receivables | 3.2m |
Other Current Assets | 1.6m |
Non-Current Assets | 17.5m |
Long-Term Investments | 54k |
PP&E | 1.4m |
Intangibles | 16m |
Current Liabilities | 4.7m |
Accounts Payable | 1.6m |
Accrued Liabilities | 1.2m |
Other Current Liabilities | 1.9m |
Non-Current Liabilities | 1.6m |
Long-Term Debt | 810k |
Other Non-Current Liabilities | 776k |
Earnings Waterfall
ImpediMed Ltd
Revenue
|
10.3m
AUD
|
Cost of Revenue
|
-1.3m
AUD
|
Gross Profit
|
9m
AUD
|
Operating Expenses
|
-30.2m
AUD
|
Operating Income
|
-21.2m
AUD
|
Other Expenses
|
1.4m
AUD
|
Net Income
|
-19.8m
AUD
|
Free Cash Flow Analysis
ImpediMed Ltd
AUD | |
Free Cash Flow | AUD |
IPD Profitability Score
Profitability Due Diligence
ImpediMed Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
ImpediMed Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
IPD Solvency Score
Solvency Due Diligence
ImpediMed Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
ImpediMed Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPD Price Targets Summary
ImpediMed Ltd
According to Wall Street analysts, the average 1-year price target for IPD is 0.148 AUD with a low forecast of 0.091 AUD and a high forecast of 0.2 AUD.
Dividends
Current shareholder yield for IPD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IPD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
Contact
IPO
Employees
Officers
The intrinsic value of one IPD stock under the Base Case scenario is 0.079 AUD.
Compared to the current market price of 0.055 AUD, ImpediMed Ltd is Undervalued by 30%.